Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

José M Ramos; Mariana F García-Sepulcre; Juan C Rodríguez; Sergio Padilla; Félix Gutiérrez

doi:10.1099/jmm.0.017277-0

Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

J Med Microbiol. 2010 May;59(Pt 5):617-621. doi: 10.1099/jmm.0.017277-0. Epub 2010 Feb 4.

Authors

José M Ramos¹, Mariana F García-Sepulcre², Juan C Rodríguez³, Sergio Padilla¹, Félix Gutiérrez¹

Affiliations

¹ Infectious Diseases Unit, Internal Medicine Department, Hospital General Universitario de Elche, Alicante, Spain.
² Digestive Section, Hospital General Universitario de Elche, Alicante, Spain.
³ Microbiology Section, Hospital General Universitario de Elche, Alicante, Spain.

PMID: 20133411
DOI: 10.1099/jmm.0.017277-0

Abstract

Mycobacteria other than tuberculosis infections in patients taking various tumour necrosis factor (TNF)-alpha inhibitors have been reported in the literature. We describe sporotrichoid spread of Mycobacterium marinum in a man with Crohn's disease treated with infliximab. After starting ethambutol and rifampicin and discontinuing infliximab, a worsening appeared. M. marinum infection may have a potential local spread and systemic dissemination in patients treated with TNF-alpha inhibitors.

Publication types

Case Reports

MeSH terms

Adult
Antitubercular Agents / therapeutic use
Crohn Disease / complications*
Crohn Disease / drug therapy*
Ethambutol / therapeutic use
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use*
Male
Mycobacterium Infections, Nontuberculous / diagnosis*
Mycobacterium Infections, Nontuberculous / microbiology
Mycobacterium marinum / isolation & purification*
Rifampin / therapeutic use
Skin / pathology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antitubercular Agents
Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Ethambutol
Rifampin